Welcome to our dedicated page for Cullinan Therapeutics news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Therapeutics stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a forward-thinking biopharmaceutical company dedicated to establishing new standards of care for patients through innovative cancer and autoimmune therapies. The company specializes in a modality-agnostic approach, targeting key drivers of disease and harnessing the immune system to eradicate diseased cells.
With a highly experienced team of oncology professionals and drug developers, Cullinan boasts a diversified portfolio of clinical-stage assets sourced from both internal and external collaborations. This includes therapies aimed at inhibiting disease drivers or activating the immune system to address various oncology and autoimmune indications.
Recent Achievements:
- CLN-617: A first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, shown to activate a broad immune response.
- CLN-619: A first-in-class monoclonal antibody for relapsed/refractory multiple myeloma, aimed at restoring immune recognition of tumor cells.
- CLN-978: A novel CD19xCD3 bispecific T cell engager being developed for systemic lupus erythematosus.
- Zipalertinib: An EGFR inhibitor for non-small cell lung cancer, with promising efficacy and a manageable safety profile.
Financially, Cullinan is well-positioned, having announced a $280 million private placement to support ongoing research and development activities. This funding, combined with current assets, is expected to sustain the company's operations into 2028.
For more detailed insights and updates, visit Cullinan’s website or follow them on LinkedIn and Twitter.
Cullinan Oncology (CGEM) announced the granting of stock options for 279,100 shares to four new employees as an inducement for employment. The options were awarded outside the 2021 Stock Option and Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Three employees received options for 129,100 shares at an exercise price of $10.99, and one employee received options for 150,000 shares at $12.04, both reflecting the closing prices on their respective grant dates. Each option vests over four years upon continued service.
Cullinan Oncology (Nasdaq: CGEM) provided updates on CLN-081, its lead program targeting EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The latest Phase 1/2a trial data shows a confirmed overall response rate of 41% at the 100mg BID dose with a favorable safety profile, including no Grade 3 or greater treatment-related adverse events. The FDA granted CLN-081 Breakthrough Therapy Designation, enabling a small food effect study before a pivotal trial expected to begin in 2H 2022. Further data will be presented at medical conferences later this year.
Cullinan Oncology (Nasdaq: CGEM) reported significant clinical advancements and financial results for Q4 2021 and the full year. The company highlighted the Phase 1/2a trial of CLN-081, achieving a 97% response rate in NSCLC patients. CLN-081 received Breakthrough Therapy Designation from the FDA, and patient dosing for CLN-619 and CLN-049 began in December 2021. Cullinan ended 2021 with over $430 million in cash, sufficient to fund operations through 2024. However, the company recorded a net loss of $34.4 million in Q4 and $67.5 million for the full year, primarily due to increased R&D expenses.
Cullinan Oncology (Nasdaq: CGEM) will hold a regulatory update webinar on CLN-081 on March 28, 2022, at 4:30 p.m. ET. Participants can register through the events section on the company's investor website. CLN-081 is an orally available, irreversible EGFR inhibitor targeting specific mutations in non-small cell lung cancer. The company is currently evaluating various doses in a Phase 1/2a trial for patients who have undergone platinum-based chemotherapy. An archived recording of the webinar will be available on the Cullinan website for 30 days.
Cullinan Oncology, focused on developing targeted cancer therapies, announced participation in the Barclays Healthcare Conference in Miami from March 15-17, 2022. CEO Nadim Ahmed will present on March 16 at 3:20 p.m. ET. A live webcast of the presentation will be available on the investor relations website, with an archive accessible for 30 days post-event. Management will also engage in one-on-one investor meetings throughout the conference. Cullinan aims to deliver innovative treatments through internal and external collaborations.
Cullinan Oncology, Inc. (NASDAQ: CGEM) has announced the selection of five abstracts for poster presentations at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. The company will showcase data from its innovative immuno-oncology pipeline, including CLN-049, CLN-619, CLN-617, CLN-978, and a novel PD-1 x CD137L fusion protein. These programs focus on enhancing cancer therapy through various mechanisms, showcasing promising preclinical and clinical results aimed at improving treatment outcomes for cancer patients.
Cullinan Oncology (NASDAQ: CGEM) announced significant leadership changes, appointing Dr. Jeffrey Jones as Chief Medical Officer and Dr. Anne-Marie Martin to its Board of Directors. Dr. Jones, previously with Bristol Myers Squibb, brings extensive oncology development experience, while Dr. Martin has over 25 years in translational medicine, most recently at GlaxoSmithKline. CEO Nadim Ahmed emphasized that their expertise will enhance Cullinan's capabilities in late-stage drug development as the company advances its pipeline of targeted cancer therapies.
Cullinan Oncology will participate in SVB Leerink’s 11th Annual Global Healthcare Conference, held virtually from February 14-18, 2022. CEO Nadim Ahmed will host a fireside chat on February 17 at 8:40 a.m. ET, available via a live webcast on the company's investor relations website. Post-event, an archive will be accessible for 30 days. The management will also engage in one-on-one meetings with investors during the conference. Cullinan focuses on developing targeted therapeutic candidates for cancer patients through innovative internal and external collaborations.
Cullinan Oncology (NASDAQ: CGEM) has entered a collaboration with the Icahn School of Medicine at Mount Sinai to develop oral protein degraders targeting HPK1, a key immune-oncology target. This multi-year agreement allows Cullinan to fund the research while holding an exclusive option to license any resulting intellectual property. The collaboration aims to enhance anti-tumor immunity through innovative therapies, co-led by experts from both institutions. The partnership reflects Cullinan's commitment to advancing cancer treatments through its diversified pipeline.
Cullinan Oncology (Nasdaq: CGEM) will present at two virtual healthcare conferences in January 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 13 at 7:30 a.m. ET. A live webcast will be available on the company’s investor relations website. Additionally, the HC Wainwright BioConnect Conference will provide on-demand presentations starting January 10 at 7:00 a.m. ET. Details for registration and access can be found on their respective websites.
FAQ
What is the current stock price of Cullinan Therapeutics (CGEM)?
What is the market cap of Cullinan Therapeutics (CGEM)?
What does Cullinan Therapeutics, Inc. specialize in?
What is CLN-617?
What is the purpose of the recent $280 million private placement?
What is Zipalertinib?
What are the latest developments regarding CLN-619?
What types of diseases does Cullinan Therapeutics' portfolio address?
What is the strategic focus of Cullinan Therapeutics?
What is CLN-978 and its target indication?
How does Cullinan Therapeutics ensure the development of promising assets?
Where can I find more information about Cullinan Therapeutics?
